Company

About

a:head bio

a:head bio

Vienna, Austria

a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement. The technology has been pioneered by the company’s co-founders Madeline Lancaster and Juergen Knoblich and is exclusively licensed to a:head by the Institute of Molecular Biotechnology, Vienna, Austria. a:head applies these complex 3D tissue cultures for modelling of various brain disorders in a human context and aims at translating the technology into a powerful high content, high throughput phenotyping platform for the development of novel CNS therapeutics.

Angios Biotech

Angios Biotech

Innsbruck, Tyrol, Austria

Angios is a biotechnology company, specializing in vascular research to improve patients' lives all over the world. We are based in the beautiful city of Innsbruck. We strive to develop new treatments for challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.

AOP Health

AOP Health

Vienna, Austria

Previously known as AOP Orphan, AOP Health is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families as well as also the doctors and care professionals treating them. Needs. Science. Trust. The international healthcare group focuses on research, development and global sales of innovative treatment solutions. AOP Health believes it has a responsibility to make innovative integrated therapies and disease-management solutions available long term to as many patients as possible who suffer from rare diseases or require critical care.

Austrianova Biotechnology

Austrianova Biotechnology

Maria Enzersdorf, Austria

Austrianova encapsulates living cells in tiny cellulose beads. The beads act as a microenvironment for living cells, allowing them to be metabolically active and divide, whilst being protected from the environment both in vivo (immunoprotection) and in vitro (sheer force, freezing stress protection). Cell-in-a-Box® enables allogenic or xenogenic mammalian cells to be protected from rejection by the immune system, but their porous nature allows therapeutic bioproducts to be released and encapsulated cells to survive for long periods. Cell-in-a-Box® has many advantages e.g. 1) clinically proven safety and efficacy upon implantation of encapsulated cells in patients 2) cells can grow within the capsules in bioreactors and are thus protected from shear forces - especially useful for fragile cells such as stem cells 3) freezing and storage of encapsulated mammalian cells at -80C for more than 5 years and then revival with greater than 90% viability, thus cells can be easily transported on dry ice. Bac-in-a-Box® enables probiotic bacteria and yeast to be encapsulated to protect them from harsh environments. Bac-in-a-Box® has a number of advantages e.g. 1) it is based on a natural polymer which is digestible 2) it totally protects probiotics from low pH as found in the stomach for extended periods (hours), allowing almost 100% of ingested probiotic cells to reach and be released in the lower intestine 3) it allows freeze drying of probiotics without appreciable loss of viability so they can be easily stored and transported at room temperature. We offer cell encapsulation R&D and cGMP production for both - mammalian cells (stem cells, engineered cell lines etc) all the way from the lab to clinical trial material (Cell-in-a-Box®) and for - bacteria and yeast encapsulation for excellent long term storage at ambient temperatures as well as 5 to 7 logs better protection from acid degradation in the stomach and later release in the large intestine (Bac-in-a-Box®).

Innovacell GmbH

Innovacell GmbH

Innsbruck, Austria

Innovacell Biotechnologie AG is an innovative biotechnology company that develops personalized cell therapies for treatment of incontinence.